Loading...
•
Sep 30, 2020
Amicus Therapeutics Q3 2020 Earnings Report
Announced third quarter 2020 financial results and corporate updates.
Key Takeaways
Amicus Therapeutics announced financial results for the third quarter ended September 30, 2020. Galafold 3Q20 Revenue was $67.4 Million and the Company is on-track to achieve Revenue Guidance of $250M-$260M.
Galafold 3Q20 Revenue of $67.4 Million.
On-Track to Achieve Revenue Guidance of $250M-$260M
AT-GAA Phase 3 PROPEL Study Readout in 1Q21 and Rolling BLA Submission to Begin in 4Q20
Positive CLN6 Batten Disease Gene Therapy Data Presented in October
Amicus Therapeutics
Amicus Therapeutics
Amicus Therapeutics Revenue by Segment
Revenue by Segment
Galafold Revenue
CapyFin.com Forward Guidance
The Company also summarized recent program updates and reiterated its full-year 2020 guidance.